MiNK Therapeutics, Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $1.9M | — | $1.2M | — | — | — | $1.1M |
| SG&A Expense | — | $1.3M | — | $1.7M | — | — | — | $1.8M |
| Operating Income | — | $-3.2M | — | $-2.9M | — | — | — | $-3.2M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | $-2.0K | — | $-4.0K | — | — | — | $-25.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-3.1M | — | $-2.7M | — | — | — | $-2.9M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.62 | — | $-0.57 | — | — | — | $-0.65 |
| EPS (Diluted) | — | $-0.62 | — | $-0.57 | — | — | — | $-0.65 |
| Shares Outstanding (Basic) | 5.1M | 5.0M | 5.0M | 4.8M | 5.0M | 4.7M | 4.7M | 4.4M |
| Shares Outstanding (Diluted) | 5.1M | 5.0M | 5.0M | 4.8M | 5.0M | 4.7M | 4.7M | 4.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |